Home About us Events Media data Subscribe Links News Email alert Search Contact us Blog  
Industry Insight
Discovery Technology
Analytical Laboratory Technology
Biopharma
Manufacturing
Delivery Systems
Ingredients, Formulation and Finishing
Bioprocessing
View our other publications with free access to extensive archives
  To print this article:
Existing subscribers please log in:
  
  USER NAME  
  PASSWORD  
   Or select

Or become a subscriber
 		 
 
 

RNA Therapy: The Next Nig Thing after mAbs?

Will RNA therapies follow in the footsteps of monoclonal antibodies as the next major development for the biopharmaceutical industry? Advances have been made, along with some setbacks – but ultimately the issue of delivery will be the single greatest challenge.

By Giles Somers at Datamonitor (September 2009)

Keywords: sales growth, success, mAbs, RNA therapy, monoclonal antibodies,

    View full article    |    Back to Biopharma section




Advair,Flovent,VentolinSymbicort,Serevent,FlonaseAstelin Rhinocort
IPTonline © 2004 The Pharmaceutical Technology Journal | Terms and Conditions | info@iptonline.com | UK Contacts |
Providing a platform of communication on new ideas, developments and innovations | UK Tel No. +44 20 77243456 | Back to top of page |